July 29, 2021
Article
Data show a patient aged 65 years would have an extrapolated mean event-free survival of 6.2 years for placebo and 8.3 years for dapagliflozin, at a gain of 2.1 years.
July 28, 2021
Video
In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space.
Data show dapagliflozin was projected to add 0.63 quality-adjusted life-years at an incremental lifetime cost of $42, 800.
July 27, 2021
Data show no significant difference in time to first heart failure rehospitalization or death compared to usual care in patients with HFrEF.
July 23, 2021
New guidelines on aortic valve implantation in risk groups with aortic stenosis shifted from risk strata to a focus on patient age and life expectancy.
July 22, 2021
Data show a significant association between wearable tracker use and increased physical activity during a 15-week period.
July 06, 2021
The EMPEROR-Preserved trial demonstrated safety and efficacy of empagliflozin for patients with heart failure across spectrum of ejection fraction.
June 10, 2021
Dapagliflozin and the SGLT2 inhibitor class may have untapped potential far beyond the reduction of heart failure hospitalization risk.
June 03, 2021
Resolution of iron deficiency was associated with lower mortality; however, mortality risk was similar following resolution of anemia.
May 17, 2021
Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.
